Navigation Links
Shire to present ADHD treatments scientific data at American Psychiatric Assoc. Meeting
Date:5/1/2008

PHILADELPHIA May 1, 2008 Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced today that it will present key scientific data on its Attention Deficit Hyperactivity Disorder (ADHD) treatments, lisdexamfetamine dimesylate, methylphenidate transdermal system and the investigational non-stimulant treatment under FDA review, guanfacine extended release, at the American Psychiatric Association (APA) annual meeting to be held May 3rd to 8th in Washington, D.C.

Shire is committed to the advancement of ADHD research, and we are pleased to be presenting the efficacy and safety results from several studies of our ADHD treatments, said Gwendolyn Niebler, Vice President of Global Medical Affairs at Shire. We believe the physician community will find the lisdexamfetamine dimesylate, methylphenidate transdermal system and guanfacine extended release study findings to be presented at APA a relevant contribution to the growing body of research on our ADHD treatment options.

A summary of the key scientific presentations is provided below. Information about these data presentations mentioned in this release is embargoed until the respective presentation sessions have taken place at the meeting.

Lisdexamfetamine Dimesylate:
May 7, 2008; 12:00 p.m. ET
Lisdexamfetamine Dimesylate Treatment in Children Diagnosed with ADHD: Parental Impressions and Experiences
APA Poster Presentation # NR6-025

May 8, 2008; 11:00 a.m. ET
Efficacy and Safety of Lisdexamfetamine Dimesylate in Adults with ADHD
APA Oral Presentation Session # 28

Methylphenidate Transdermal System:
May 7, 2008; 12:00 p.m. ET
Long-Term Treatment Effects of the Methylphenidate Transdermal System in Boys and Girls with ADHD
APA Poster Presentation # NR6-018

Guanfacine Extended Release:
May 7, 2008; 12:00 p.m. ET
Guanfacine Extended Release: Duration of Effect in Children and Adolescents Aged 6 to 17 Years With ADHD
APA Poster Presentation # NR6-008

May 7, 2008; 12:00 p.m. ET
Response to Guanfacine Extended Release in Children and Adolescents Aged 6 to 17 Years With ADHD
APA Poster Presentation # NR6-040


'/>"/>

Contact: Lucia Lodato
212-601-8037
Porter Novelli
Source:Eurekalert

Related medicine news :

1. AUDIO from Medialink and Shire: What It Means to be an Adult With ADHD
2. Shire Launches Patient Education Forums on Better Managing the Challenges of Ulcerative Colitis
3. VIDEO from Medialink and Shire plc: Rare Diseases Must Be Top of the Health Agenda
4. New Hampshire AIDS Group Calls on Huckabee to Disavow His 1992 Statement
5. Shire to Present New Scientific Data on its ADHD Treatments at a Major Psychiatric Meeting
6. New Hampshire: 1st in the Nation Primary State Takes a Stand on E-Prescribing
7. Families Invited to Celebrate Shire Day at Boston Childrens Museum
8. URAC CEO Testifies Before New Hampshire Legislators Regarding New URAC Standards for Pharmacy Benefit Management
9. Exciting New Plan from John Edwards on AIDS; Plan is Bold and Achievable, say New Hampshire Activists
10. Haemacure to Present at the BioFinance 2008 Conference to be held at the Toronto Marriott Eaton Centre, May 6 - 8, 2008
11. Paloma Pharmaceuticals Presents at the Association for Research in Vision and Ophthalmology Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... The Gluten-Free Certification Program ... to announce the launch of the GFCP Scoop in response to ... purpose of the GFCP Scoop site is to keep the gluten-free ...
(Date:4/29/2016)... ... April 29, 2016 , ... Dr. Robert Mondavi, one of the ... Cosmetic dentistry is a fast-growing field as more patients are discovering the many different ... more about the options currently available to them and which ones might work for ...
(Date:4/29/2016)... , ... April 29, 2016 , ... Reltok Nasal Products ... products for the head and neck/ear, nose and throat specialty, has added the KOTLER ... The KOTLER NASAL AIRWAY™ is a newly patented safety device secured by nasal ...
(Date:4/29/2016)... ... April 29, 2016 , ... Jvion, ... round of funding led by Eastside Partners, with participation from existing investor Martin ... customer base and accelerate its technology and product roadmap. , “Jvion ...
(Date:4/29/2016)... ... 2016 , ... Regenerative Medicine Solutions (RMS) scored 94.8124 out of ... them second place for Tampa’s Best Places to Work. They were ranked in the ... great accomplishment for our team,” says RMS Human Resources Manager Irene Miller. “We work ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... , April 28, 2016   Click here ... Pharmacy, Inc. (NYSE: DPLO), the nation,s largest independent ... a definitive agreement to acquire Valley Campus Pharmacy, ... ("TNH"), a leading specialty pharmacy that provides individualized ... California . In 2015, TNH generated approximately ...
(Date:4/28/2016)... April 28, 2016  The blood testing market in ... according to Kalorama Information and The Freedonia Group in ... nucleic acid testing.  The healthcare research firm said that ... developing blood collection stations and in improving testing at ... Information,s report, Blood Testing Market in China ...
(Date:4/28/2016)... 28, 2016   Acsis , a leading provider ... IT market research and advisory firm IDC has named ... MarketScape: Worldwide Pharmaceutical Track and Trace Software 2016 Vendor ... an assessment of the capabilities and business strategies of ... market. Logo - http://photos.prnewswire.com/prnh/20160427/360791LOGO ...
Breaking Medicine Technology: